Research Focus

Former Employee. Non-Divisional Cost; Research Asst

Recent additions – View all

1. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma

   Journal Article

   Toner, L. E.; Vrhovac, R.; Smith, E. A.; Gardner, J.; Heaney, M.; Gonen, M.; Teruya-Feldstein, J.; Sirotnak, F.; O'Connor, O. A.
   Clinical Cancer Research (2006)

   Fulltext@MSK | Save
2. The combination of the proteasome inhibitor bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide

   Journal Article

   O'Connor, O. A.; Smith, E. A.; Toner, L. E.; Teruya-Feldstein, J.; Frankel, S.; Rolfe, M.; Wei, X.; Liu, S.; Marcucci, G.; Chan, K. K.; more...
   Clinical Cancer Research (2006)

   Fulltext@MSK | Save
3. Targeting antiapoptotic Bcl-2 family members with AT-101 in pre-clinical models of aggressive lymphoma in combination with cyclophosphamide (C) and rituximab (R) produces a marked improvement in therapeutic efficacy

   Meeting Abstract

   Paoluzzi, L.; Gonen, M.; Toner, L.; Smith, E.; Yang, D.; Holmund, J.; Sorensen, M.; O'connor, O.
   Blood (2005)

   Fulltext@MSK | Save